Canaccord Genuity Rates Hims & Hers Health (HIMS) buy

Canaccord Genuity maintains a buy rating on Hims & Hers Health, Inc. with a $40 price target, a 4.85% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 10:00 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Hims & Hers Health, Inc. ($HIMS) "buy" with a $40 price target on July 1, 2026.

Since the rating, $HIMS is down 4.0% after 1 week, down 26.1% after 1 month and down 25.3% to date (from the $37.57 close on Jul 1, 2026).

HIMS Hims & Hers Health, Inc.

$28.07 -15.98% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity reiterated its buy rating on Hims & Hers Health, Inc. (NYSE:HIMS) with a $40 price target on July 1, 2026.
Canaccord Genuity's $40 price target implies 4.85% upside from Hims & Hers Health, Inc.'s ($HIMS) current $38.15 share price.
Shares of HIMS traded at $34.17 on Wednesday, with a market cap of $8.02 billion and a forward P/E ratio of 39.0.
Insider transactions include planned sales by the CFO and CTO, while analysts like B of A Securities and Barclays also maintain their ratings.

Get $HIMS trade alerts by text

We text you when insiders, Congress or big funds trade $HIMS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hims & Hers Health, Inc. alert may contain errors. Disclosures

On July 1, 2026, Canaccord Genuity reiterated its buy rating on Hims & Hers Health, Inc. (NYSE:HIMS), setting a price target of $40. Shares of the company traded at $34.17 on Wednesday.

Analyst rating track record

Canaccord Genuity vs. the S&P 500

YTD return -31.96% hypothetical

All-time return +10.48% S&P 500 +39.16%

vs. S&P 500 -28.68% behind the index

Hypothetical returns from Canaccord Genuity's disclosed trades, not real profit or advice. How we model this.

Hims & Hers Health, Inc. Stock Up 37.6%

Shares of NYSE:HIMS traded near $34.17 on Wednesday. The company has a market cap of approximately $8.02 billion and a forward P/E ratio of 39.0. With a beta of 2.398, the stock has experienced a 52-week low of $13.74 and a high of $70.43. Its 50-day moving average stands at $27.97, while the 200-day moving average is $32.92.

12-month forecast

$HIMS price target

Hims & Hers Health, Inc. daily closes and this analyst's $40 target. Not advice.

Insider Buying and Selling at Hims & Hers Health, Inc.

Several insider transactions took place recently. On June 22, 2026, Chief Financial Officer Oluyemi Okupe sold 18,197 shares at an average price of $34.03 under a planned sale. On the same day, Okupe also sold an additional 6,376 shares without a plan and purchased 6,376 shares at $5.01. Chief Medical Officer Patrick Harrison Carroll sold 23,726 shares at $35.00 on June 18, 2026, under a planned sale. CTO Mohamed Elshenawy and PAO Irene Becklund also made planned sales on June 17, 2026.

Analysts Set New Price Targets

On July 1, 2026, Canaccord Genuity maintained its buy rating with a $40 price target for Hims & Hers Health, Inc. B of A Securities also maintained a hold rating with a $36 target. Earlier, on June 18, 2026, Barclays maintained a buy rating with a $39 price target. The consensus among analysts is a hold rating with a mean target price of $27.32, based on 14 opinions.

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. is a healthcare platform based in San Francisco, California. It connects consumers with licensed healthcare professionals and offers a range of health and wellness products. These include prescription and non-prescription products, cosmetics, and supplements. The company operates in several countries, including the U.S., U.K., and Canada, and is led by CEO Andrew Dudum.

Bottom Line

Hims & Hers Health, Inc. continues to draw attention from analysts, with Canaccord Genuity reiterating its buy rating and setting a $40 price target. The company's stock performance shows volatility, reflected in its high beta and wide 52-week range. Investors keep a close eye on insider transactions and analyst ratings to gauge market sentiment. Remember, the ratings and targets are based on past data and may not reflect the current market conditions.